Welcome to LookChem.com Sign In|Join Free

CAS

  • or

234082-05-4

Post Buying Request

234082-05-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

234082-05-4 Usage

General Description

Ethyl 4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzoate is a chemical compound with the molecular formula C17H24N2O2. It is a derivative of benzoic acid and contains a piperazine ring substituted with two methyl groups. ethyl 4-((3S,5R)-3,5-diMethylpiperazin-1-yl)benzoate is often used as an intermediate in the manufacturing of pharmaceuticals, specifically in the synthesis of drugs that act on the central nervous system. Its unique molecular structure makes it a valuable building block for the development of new medications and pharmaceutical products. Additionally, its piperazine moiety makes it a potential candidate for the treatment of various neurological and psychiatric disorders. Overall, ethyl 4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzoate has diverse applications in the pharmaceutical industry due to its interesting structural properties and potential therapeutic benefits.

Check Digit Verification of cas no

The CAS Registry Mumber 234082-05-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,4,0,8 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 234082-05:
(8*2)+(7*3)+(6*4)+(5*0)+(4*8)+(3*2)+(2*0)+(1*5)=104
104 % 10 = 4
So 234082-05-4 is a valid CAS Registry Number.

234082-05-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 4-{cis-3,5-dimethylpiperazin-1-yl}benzoate

1.2 Other means of identification

Product number -
Other names 4-((3R,5S)-3,5-Dimethyl-piperazin-1-yl)-benzoic acid ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:234082-05-4 SDS

234082-05-4Relevant articles and documents

New and convergent synthesis of AZD 4547

Bu, Lehao,Chen, Wenxin,Gao, Lei,Mao, Yongjun,Sun, Cong,Wang, Han

, p. 276 - 282 (2020/06/10)

A practical and convergent synthetic route of AZD 4547 was developed successfully. The intermediate 5-(3,5-dimethoxyphenylethyl)-1H-pyrazol-3-amine (7) was prepared from 3,5-dimethoxybenzaldehyde through 6 simple steps in 52.3% yield. Another intermediate 4-((3S,5R)-3,5-dimethylpiperazin-1-yl)benzoic acid (14) was synthesized from ethyl 4-fluorobenzoate and (2R,6S)-2,6-dimethylpiperazine in 62% yield over 2 steps. Finally, AZD 4547 was obtained from 7 and 14 in 73% yield and 99.1% purity. Purification methods of the intermediates and the final product involved in the route were developed.

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Wei, Manman,Peng, Xia,Xing, Li,Dai, Yang,Huang, Ruimin,Geng, Meiyu,Zhang, Ao,Ai, Jing,Song, Zilan

, p. 9 - 28 (2018/05/28)

Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50 values less than 5.0 nM. Significant antiproliferative effects on both FGFR1/2 and VEGFR2 aberrant cancer cells were observed. In the SNU-16 xenograft model, compound 25a showed tumor growth inhibition rates of 25.0% and 81.0% at doses of 10 mg/kg and 50 mg/kg, respectively, with 5% and 10%body weight loss. In view of the synergistic potential of FGFs and VEGFs in tumor angiogenesis observed in preclinical studies, the FGFR/VEGFR2 dual inhibitor 25a may achieve better clinical benefits.

Development of an SNAr Reaction: A Practical and Scalable Strategy to Sequester and Remove HF

Blacker, A. John,Moran-Malagon, Gabriel,Powell, Lyn,Reynolds, William,Stones, Rebecca,Chapman, Michael R.

, (2018/09/27)

A simple and operationally practical method to sequester and remove fluoride generated through the SNAr reaction between amines and aryl fluorides is reported. Calcium propionate acts as an inexpensive and environmentally benign in situ scrubbe

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 234082-05-4